Literature DB >> 16426016

Can the level of immunosuppression in human immunodeficiency virus-infected patients affect the reliability of human T-cell lymphotropic virus type 2 serological diagnosis?

Sylvina Bassani1, Carlos Toro, Victoria Jiménez, Berta Rodés, Vincent Soriano.   

Abstract

A total of 175 human immunodeficiency virus (HIV)-positive intravenous drug users (IDU) with CD4 cell counts of <200 cells/microl were matched with 175 HIV-positive IDU with CD4 cell counts of >500 cells/microl. Enzyme immunoassay (EIA) reactivity and human T-cell lymphotropic virus type 2 (HTLV-2) Western blot (WB) positivity were more frequently observed in subjects with CD4 cell counts of >500 cells/microl. Most of the subjects with low CD4 cell counts and EIA reactivity carried HTLV-2 infection (WB positive and/or PCR positive). No subjects with low CD4 cell counts and a lack of reactive EIA were PCR positive for HTLV-2. Therefore, a negative EIA result can confidently discharge HTLV-2 infection in HIV-infected patients with severe immunosuppression, whereas PCR should be performed for subjects with a reactive HTLV EIA which is not further confirmed by WB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426016      PMCID: PMC1356619          DOI: 10.1128/CVI.13.1.160-161.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  12 in total

1.  Absence of human T-lymphotropic virus type I tax sequences in a population of normal blood donors in the Baltimore, MD/Washington, DC, area: results from a multicenter study.

Authors:  E P Cowan; G J Nemo; A E Williams; R K Alexander; A Vallejo; I K Hewlett; R B Lal; C S Dezzutti; D Gallahan; K George; B A Pancake; D Zucker-Franklin; P R McCurdy; E Tabor
Journal:  Transfusion       Date:  1999-08       Impact factor: 3.157

2.  Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk.

Authors:  F J Medrano; V Soriano; E J Calderón; C Rey; M Gutiérrez; R Bravo; M Leal; J González-Lahoz; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

3.  Detection of human T-lymphotropic virus (HTLV) tax sequences in New York City blood donors seronegative for HTLV types 1 and 2.

Authors:  Charlene S Dezzutti; Patricia C Guenthner; Sylvester Daniel; Ursula Utz; Thania Cabrera; James H Marshall; Celso Bianco; Renu B Lal; Elliot P Cowan
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

4.  Absence of evidence of infection with divergent primate T-lymphotropic viruses in United States blood donors who have seroindeterminate HTLV test results.

Authors:  M P Busch; W M Switzer; E L Murphy; R Thomson; W Heneine
Journal:  Transfusion       Date:  2000-04       Impact factor: 3.157

5.  High prevalence of false-negative anti-HTLV type I/II enzyme-linked immunosorbent assay results in HIV type 1-positive patients.

Authors:  G Zehender; C De Maddalena; M Gianotto; B Cavalli; S Santambrogio; M Orso; M Moroni; M Galli
Journal:  AIDS Res Hum Retroviruses       Date:  1997-09-01       Impact factor: 2.205

6.  Comparative performances of an HTLV-I/II EIA and other serologic and PCR assays on samples from persons at risk for HTLV-II infection.

Authors:  B J Poiesz; S Dube; D Choi; E Esteban; J Ferrer; M Leon-Ponte; G E de Perez; J Glaser; S G Devare; A S Vallari; G Schochetman
Journal:  Transfusion       Date:  2000-08       Impact factor: 3.157

7.  Typing human T-cell lymphotropic virus (HTLV-I and HTLV-II) by nested polymerase chain reaction: application to clinical specimens.

Authors:  A Vallejo; A García-Sáiz
Journal:  J Virol Methods       Date:  1995-01       Impact factor: 2.014

8.  Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. The HTLV European Research Network.

Authors: 
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-09

9.  Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users.

Authors:  E Chamot; B Hirschel; J Wintsch; C F Robert; V Gabriel; J J Déglon; S Yerly; L Perrin
Journal:  AIDS       Date:  1990-12       Impact factor: 4.177

10.  [HIV-2 and HTLV-I/II infections in Spain].

Authors:  Carlos Toro; Berta Rodés; Antonio Aguilera; Estrella Caballero; Rafael Benito; Sylvina Bassani; Carmen Rodríguez; Concepción Tuset; Raúl Ortiz de Lejarazu; José Eirós; Juan García; Enrique Calderón; Francisco J Capote; Alejandro Vallejo; Maite Gutiérrez; Vicente Soriano
Journal:  Enferm Infecc Microbiol Clin       Date:  2004-03       Impact factor: 1.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.